Abstracts tagged "T Cell"

Abstract Number: 0983 • ACR Convergence 2025
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Grace Frechette, Thamotharampillai Dileepan, Marc Jenkins and Shawn Mahmud, University of Minnesota, Minneapolis
Background/Purpose: Mixed connective tissue disease (MCTD) is a systemic autoimmune disorder marked by a U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibody. The majority of U1-snRNP antibodies in…
Abstract Number: 0521 • ACR Convergence 2025
Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren’s disease by inducing Bach2 expression
Yukitomo Hagiwara¹, Goh Murayama², Taiga Kuga³, Yujin Nishioka⁴, Masaki Nojima¹, Takumi Saito⁵, Yu Yamaji⁶, Tomoko Miyashita⁶, Makio Kusaoi⁷, Ken Yamaji⁵ and Naoto Tamura⁸, ¹Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ³Juntendo University, Tokyo, Japan, ⁴Juntendo University, Department of Internal Medicine and Rheumatology, Shizuoka, Japan, ⁵Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ⁶Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo-ku, Tokyo, ⁷Juntendo University, Department of Internal Medicine and Rheumatology, Bunkyo, Tokyo, Japan, ⁸Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren's disease (pSD) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
Abstract Number: 2434 • ACR Convergence 2025
Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: We previously validated T Cell-bound C4d (TC4d), T Cell-bound IgG (TIgG), and T Cell-bound IgM (TIgM) biomarkers, demonstrating high sensitivity and specificity for differentiating…
Abstract Number: 1005 • ACR Convergence 2025
CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
Yusuke Miyashita¹, Yang Yang², Madison Mangin³, Maryrose Hahn² and Margaret Chang², ¹Boston Children's Hospital, Brookline, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease featured with recurrent inflammation in the same joints, a characteristic termed joint-specific memory. We previously demonstrated…
Abstract Number: 0980 • ACR Convergence 2025
Expansion of Viral-Reactive CD8+ T cell Repertoire Stratified by Pathotype in New-onset ACPA+ Rheumatoid Arthritis
Carl Coyle¹, Wittaya Suwakulsiri², Lukas Andriessen³, Megan Soon⁴, Pascale Wehr⁵, Sumera Qureshi⁶, Christopher Altmann⁷, Annabelle Small⁸, Vincent Wong⁹, Andrew Cope⁶, Kevin Wei¹⁰, Hendrik Nel⁵, Mihir Wechalekar¹¹ and Ranjeny Thomas², ¹Kings College London, London, United Kingdom, ²Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ³Frazer Institute, University of Queensland, Woolloongabba, Queensland, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia, ⁵University of Queensland, Woolloongabba, Queensland, Australia, ⁶King's College London, London, United Kingdom, ⁷Flinders University, Adelaide, Australia, ⁸Flinders University, Bedford Park, South Australia, Australia, ⁹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Flinders Medical Centre, Adelaide, Australia
Background/Purpose: Development of Rheumatoid Arthritis (RA) is strongly associated with specific HLA-DRB1 genotypes and the HLA-DR antigen binding groove, the shared epitope. HLA-B*08 also increases…
Abstract Number: 0471 • ACR Convergence 2025
An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Fredrik Albach¹, Ioanna Minopoulou¹, Artur Wilhelm², Robert Biesen¹, Arnd Kleyer¹, Norman Drzeniek³, Edgar Wiebe⁴, Anja Fleischmann³, Dominic Borie⁵, Vincent Casteleyn³, Tobias Alexander³, Christian Furth⁶, Jan Zernicke³, Burkhard Muche⁷, Sandra Hermann⁴, Pfeil Alexander⁸, Veronika Scholz³, Elpida Phithak³, Olaf Penack⁹, Kamran Movassaghi⁹, Eva Vanessa Schrezenmeier¹⁰, Udo Schneider³, Antonia Busse¹¹, Georg Schett¹², Ulrich Keller¹¹, Lars Bullinger⁹, Gerhard Krönke¹³, Marie Luise Hütter-Krönke¹⁴ and David Simon¹⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Kyverna Therapeutics, Emeryville, CA, ⁶Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁷Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁸Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁹Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, ¹⁰Department of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ¹¹Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; German Cancer Consortium (DKTK) partner site Charité Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany, Berlin, ¹²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ¹⁴Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany, Berlin, ¹⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by autoreactive B cells that produce anti-citrullinated protein antibodies (ACPA), contributing to sustained synovial inflammation…
Abstract Number: 2303 • ACR Convergence 2025
Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
Ruiling Feng, Bo Huang and Yuebo Jin, Peking University People’s Hospital, Beijing, China (People's Republic)
Background/Purpose: Low-dose interleukin 2 (Ld-IL2) is increasingly being explored as an immune-modulating treatment for autoimmune diseases which mainly affect T cell subsets. This study investigates…
Abstract Number: 1004 • ACR Convergence 2025
Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Yang Yang¹, Yusuke Miyashita², Madison Mangin³, Kellen Winden¹, Peter Nigrovic² and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We…
Abstract Number: 0979 • ACR Convergence 2025
IL-23 upregulates IFN-γ secretion in Th17.1, but not in Th17 or classical Th1 cells
Bennie van Heeswijk¹, Wida Razawy², Anne-Marie Mus-Otten³, Patrick Asmawidjaja², Pieter Leenen² and Erik Lubberts⁴, ¹Erasmus MC, University Medical Center Rotterdam, Hoofddorp, Netherlands, ²Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands, ³Erasmus medical center, Rotterdam, Netherlands, ⁴Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
Background/Purpose: Interleukin-23 (IL-23) is a key cytokine in the pathogenesis of psoriatic diseases, as demonstrated by the clinical success of IL-23-targeted therapies. Monocytes are a…
Abstract Number: 0273 • ACR Convergence 2025
Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Synat Keam¹, Yuanteng Li², Yanshuo Chu¹, Jean Tayar³, Huifang Lu⁴, Michael Wu⁵, Sandeep Agarwal⁶, Nitin Jain⁷, Pavlos Msaouel¹, Adi Diab², Cara Haymaker¹, Linghua Wang¹, Roza Nurieva⁸ and Sang Kim⁹, ¹The University of Texas MD Anderson Cancer Center, houston, ²MD Anderson Cancer Center, Houston, TX, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Baylor College of Medicine, Houston, ⁶Baylor College of Medicine, Houston, TX, ⁷The Universty of Texas MD Anderson Cancer Center, Houston, ⁸University of Texas MD Anderson, Houston, TX, ⁹Yale University, Branford, CT
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is associated with life- and/or organ-threatening immune-related adverse events, including inflammatory arthritis (ICI-IA). However, the mechanisms behind ICI-IA, especially…
Abstract Number: 2293 • ACR Convergence 2025
CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Ella Ioffe, Karsten Sauer, Todd Shearer, Jennifer Michaelson, Jeffrey Jones, Yue Zhang, Stephen Wax and Antoine Sreih, Cullinan Therapeutics Inc, Cambridge, MA
Background/Purpose: Treatments depleting CD19-expressing B cells have shown benefit in a range of autoimmune diseases. T cell engagers (TCE) offer off-the-shelf convenience, the predictable pharmacokinetic/pharmacodynamic…
Abstract Number: 1001 • ACR Convergence 2025
LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Hongyan Shang¹, Xiao Huang², Duqing Jiang¹, Jianming Sun², Yurong Qin², Guojin Wu², Chengze Ni¹, Jing Guan², Jordan Zhu³, Xiaoqiang Kang² and Hong Ling², ¹Nanjing Leads Biolabs Co., Ltd., nanjing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ³Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Programmed cell death protein 1 (PD-1) is expressed on activated T cells and serves as a key co-inhibitory checkpoint molecule in immune regulation. Aberrant…
Abstract Number: 0950 • ACR Convergence 2025
Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
mingyang zhang¹, huanzi dai², cun lan³ and mingyang sun³, ¹Daping Hospital, Army Medical University, chongqing, Chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic), ³Daping Hospital, Army Medical University, chongqing, China (People's Republic)
Background/Purpose: Senescent CD4+ T cells are increasingly implicated in systemic lupus erythematosus (SLE) pathogenesis. While metabolic reprogramming in lupus T cells enhances glycolysis and lactate…
Abstract Number: 0110 • ACR Convergence 2025
SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
Yuka Nakao¹, Astha Patel¹, Bahram Razani², Steven yu¹, Steven Lazarevsky², Marlys Fassett² and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²UCSF Department of Dermatology, San Francisco, CA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are chronic immune-mediated diseases affecting millions, yet early immunologic triggers remain poorly defined. Therapies targeting TNFα, IL-17, and…
Abstract Number: 2277 • ACR Convergence 2025
Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
John Bui¹, Jason Dubovsky², Jennifer Abrams³, Sara Charmsaz⁴, Michelle Blake¹, Joshua Beilke⁴, Anne-Renee van der Vuurst de Vries¹, Joseph Arron⁵, Jonathan Graf⁶ and Jeffrey Bluestone⁷, ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, South San Francisco, ³Sonomabio, San Francisco, CA, ⁴Sonoma Biotherapeutics, Seattle, ⁵Sonoma Biotherapeutics, San Francisco, CA, ⁶UCSF, San Francisco, CA, ⁷Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Emerging cell-based therapies for rheumatoid arthritis (RA) target the underlying immunologic activity of disease. Objective biomarkers to-date are downstream sequelae of RA immunologic drivers.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].